Invention Grant
US08642621B2 (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
有权
（4-苯基 - 哌啶-1-基） - [5-（1H-吡唑-4-基） - 噻吩-3-基] - 甲酮化合物及其用途
![(4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use](/docs/US/2014-02-04/US08642621B2/abs.jpg.600x600.jpg)
- Patent Title: (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
- Patent Title (中): （4-苯基 - 哌啶-1-基） - [5-（1H-吡唑-4-基） - 噻吩-3-基] - 甲酮化合物及其用途
-
Application No.: US13395963Application Date: 2010-09-14
-
Publication No.: US08642621B2Publication Date: 2014-02-04
- Inventor: Scott Peter Webster , Jonathan Robert Seckl , Brian Robert Walker , Peter Ward , Thomas David Pallin , Hazel Joan Dyke , Trevor Robert Perrior
- Applicant: Scott Peter Webster , Jonathan Robert Seckl , Brian Robert Walker , Peter Ward , Thomas David Pallin , Hazel Joan Dyke , Trevor Robert Perrior
- Applicant Address: GB Edinburgh
- Assignee: The University Of Edinburgh
- Current Assignee: The University Of Edinburgh
- Current Assignee Address: GB Edinburgh
- Agency: Swanson & Bratschun, L.L.C.
- International Application: PCT/GB2010/001732 WO 20100914
- International Announcement: WO2011/033255 WO 20110324
- Main IPC: A61K31/451
- IPC: A61K31/451 ; C07D409/00
![(4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use](/abs-image/US/2014/02/04/US08642621B2/abs.jpg.150x150.jpg)
Abstract:
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
Public/Granted literature
- US20120172393A1 (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use Public/Granted day:2012-07-05
Information query
IPC分类:
